Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alkermes plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaPsichiatriaSaluteSanità

50 comunicati stampa

Guarda tutti i comunicati
04/06/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
Medicina - Varie
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
03/06/2026
Biotecnologia
Farmaceutica
Finanza
Salute
Psichiatria
Associazioni/Professionisti
Medicina - Varie
Eventi
Web e Social Network
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
26/05/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
21/05/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
Medicina - Varie
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
12/05/2026
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
05/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Alkermes plc Reports First Quarter 2026 Financial Results
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
21/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Psichiatria
Salute
Sanità
Farmaceutica
Biotecnologia
Alkermes to Report First Quarter Financial Results on May 5, 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
16/04/2026
Eventi
Psichiatria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
14/04/2026
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0